Bone Tumor, Soft Tissue Tumor
Conditions
Keywords
MR imaging, Diffusion weighted imaging, MR proton spectroscopy, CT perfusion, Contrast enhanced ultrasound
Brief summary
The purpose is to compare and evaluate multiple functional imaging methods (perfusion, diffusion, spectroscopy) for initial benign/malignant characterization of osteoarticular tumors and to determine which method or which association of methods could improve non invasive tissue characterization. Secondary purposes are: * to determine a possible correlation between some parameters and the histological grade (FNCLCC) * to suggest a coherent diagnostic imaging approach for osteoarticular tumors. The ancillary study will enroll patients needing radiological tumor follow-up. The purpose is to identify tools for evaluation of tumor activity and therapeutic response before modification of morpho-volumetric data.
Detailed description
Patients refered for the initial evaluation of suspected osteoarticular masses will be included in this study after signing an informed consent. Histologic analysis will be used as a gold standard. The following imaging techniques will be evaluated: * contrast enhanced ultrasonography * Low dose CT perfusion * Magnetic resonance perfusion * Diffusion weighted imaging * Magnetic resonance proton spectroscopy
Interventions
OTHEREcography
Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
OTHERCT scan
With injection of Iomeron 400
OTHERMRI
With injection of gadolinium (Multihance)
Sponsors
Central Hospital, Nancy, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients examined for initial assessment of bone or peripheral soft-tissue primitive tumor * patients with normal awareness level * patients having signed informed consent
Exclusion criteria
* pregnant women * persons deprived of liberty * persons under legal protection or unable to give informed consent * persons in life-threatening emergency * allergy to Sonovue, iodinated contrast media or gadolinium chelates * risk of pregnancy * breastfeeding women * acute coronary syndrome or unstable ischemic cardiopathy (ban on injection of contrast agent for CT scan) * renal failure (ban on injection of contrast agent for MRI and CT scan) * contraindication to MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Contrast enhancement curve (absent, slow or fast) in MRI | baseline | — |
| Maximal intensity of enhancement peak in MRI | baseline | — |
| Mean transit time of enhancement in MRI | baseline | — |
| Gradient of contrast enhancement curve in MRI | baseline | — |
| Contrast enhancement in echography: yes or no | baseline | — |
| Contrast enhancement curve (absent, slow or fast) in echography | baseline | — |
| Maximal intensity of enhancement peak in echography | baseline | — |
| Mean transit time of enhancement in echography | baseline | — |
| Gradient of contrast enhancement curve in echography | baseline | — |
| Vascularization (dynamic analysis) in CT scanner | baseline | * 0: absent * 1: low (\< 20UH) * 2: \> 20 UH without new blood vessels * 3: \> 20 UH and/or with new blood vessels |
| Contrast enhancement curve (absent, slow or fast) in CT scanner | baseline | — |
| Maximal intensity of enhancement peak in CT scanner | baseline | — |
| Mean transit time of enhancement in CT scanner | baseline | — |
| Gradient of contrast enhancement curve in CT scanner | baseline | — |
| Choline peak in magnetic resonance spectroscopy | baseline | Choline presence was defined as a clear metabolite peak at 3.2 ppm |
| Apparent diffusion coefficient (ADC) in MR diffusion weighted imaging | baseline | ADC value in mm2/s |
| Area under the perfusion curve in MRI | baseline | — |
| Perfusion curve gradient in MRI | baseline | — |
| Perfusion time-to-peak in MRI | baseline | — |
Countries
France
Contacts
Primary ContactPedro Augusto GONDIM TEIXEIRA
Outcome results
None listed